MetaADEDB 2.0 @ LMMD
Desvenlafaxine Succinate
(KYYIDSXMWOZKMP-UHFFFAOYSA-N)
Structure
SMILES
CN(CC(C1(O)CCCCC1)c1ccc(cc1)O)C
Type(s)
Approved; Investigational
ATC code(s)
N06AX23
Molecular Formula:
C16H25NO2
Molecular Weight:
263.375
Log P:
2.7326
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
2
TPSA:
43.7
CAS Number(s):
93413-62-8; 386750-22-7
Synonym(s)
1.
Desvenlafaxine Succinate
2.
2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate
3.
4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
4.
Desvenlafaxine
5.
O-desmethylvenlafaxine
6.
O-desmethylvenlafaxine Succinate
7.
O-desmethylvenlafaxine Succinate Monohydrate
8.
Pristiq
9.
WY 45,233
10.
WY 45233
11.
WY-45,233
12.
WY-45233
13.
45,233, WY
14.
45233, WY
15.
Monohydrate, O-desmethylvenlafaxine Succinate
16.
O desmethylvenlafaxine
17.
O desmethylvenlafaxine Succinate
18.
O desmethylvenlafaxine Succinate Monohydrate
19.
Succinate Monohydrate, O-desmethylvenlafaxine
20.
Succinate, Desvenlafaxine
21.
Succinate, O-desmethylvenlafaxine
22.
WY45,233
23.
WY45233
External Link(s)
MeSHD000069468
PubChem Compound125017
BindingDB86748
50010875
ChEBI83527
CHEMBLCHEMBL1118
DrugBankDB06700
DrugCentral4380
IUPHAR/BPS Guide to PHARMACOLOGY7158
KEGGdr:D07793
Therapeutic Target DatabaseD0O3FG
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 17
Canada Vigilance: 5
Canada Vigilance
OFFSIDES
US FAERS
2Product substitution issueFAERS: 16
Canada Vigilance: 5
Canada Vigilance
US FAERS
3DizzinessFAERS: 5OFFSIDES
SIDER
US FAERS
4Feeling abnormalFAERS: 5
Canada Vigilance: 2
Canada Vigilance
OFFSIDES
US FAERS
5HeadacheFAERS: 5SIDER
US FAERS
6AnxietyFAERS: 4
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
SIDER
US FAERS
7MalaiseFAERS: 4US FAERS
8Depressed moodFAERS: 3
Canada Vigilance: 2
Canada Vigilance
US FAERS
9Drug ineffective for unapproved indicationFAERS: 3US FAERS
10Abdominal discomfortFAERS: 2US FAERS
11AstheniaFAERS: 2
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
12Burning sensationFAERS: 2US FAERS
13MydriasisFAERS: 2SIDER
US FAERS
14NauseaFAERS: 2OFFSIDES
SIDER
US FAERS
15PriapismFAERS: 2US FAERS
16Product residue presentFAERS: 2US FAERS
17Sexual DysfunctionFAERS: 2SIDER
US FAERS
18Tardive DyskinesiaFAERS: 2US FAERS
19Therapeutic response changedFAERS: 2US FAERS
20Abdominal PainFAERS: 1US FAERS
21AbscessFAERS: 1US FAERS
22Acute kidney injuryFAERS: 1US FAERS
23AngerFAERS: 1OFFSIDES
US FAERS
24ApathyFAERS: 1US FAERS
25AppendicitisFAERS: 1US FAERS
26ConstipationFAERS: 1SIDER
US FAERS
27DisorientationFAERS: 1US FAERS
28Drug dose omissionFAERS: 1US FAERS
29Drug effect incompleteFAERS: 1US FAERS
30Drug withdrawal syndromeFAERS: 1US FAERS
31Emotional disorderFAERS: 1US FAERS
32Emotional distressFAERS: 1US FAERS
33FatigueFAERS: 1
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
SIDER
US FAERS
34Feeling ColdFAERS: 1US FAERS
35Feeling jitteryFAERS: 1SIDER
US FAERS
36Feelings of worthlessnessFAERS: 1US FAERS
37Hepatitis AFAERS: 1US FAERS
38Joint injuryFAERS: 1US FAERS
39Limb injuryFAERS: 1US FAERS
40Medication residue presentFAERS: 1US FAERS
41Mood swingsFAERS: 1US FAERS
42Musculoskeletal stiffnessFAERS: 1SIDER
US FAERS
43MyalgiaFAERS: 1US FAERS
44NegativismFAERS: 1US FAERS
45Night sweatsFAERS: 1US FAERS
46PalpitationsFAERS: 1SIDER
US FAERS
47PhotophobiaFAERS: 1US FAERS
48PoisoningFAERS: 1US FAERS
49Product administration interruptedFAERS: 1US FAERS
50Product quality issueFAERS: 1US FAERS
51Product solubility abnormalFAERS: 1US FAERS
52PruritusFAERS: 1US FAERS
53RestlessnessFAERS: 1US FAERS
54RhabdomyolysisFAERS: 1US FAERS
55SomnolenceFAERS: 1SIDER
US FAERS
56TachycardiaFAERS: 1SIDER
US FAERS
57Tension HeadacheFAERS: 1US FAERS
58Therapy cessationFAERS: 1US FAERS
59TremorFAERS: 1SIDER
US FAERS
60UrticariaFAERS: 1US FAERS
61Visual ImpairmentFAERS: 1US FAERS
62VomitingFAERS: 1SIDER
US FAERS
63YawningFAERS: 1OFFSIDES
SIDER
US FAERS
64Abdominal symptomOFFSIDES
65Abnormal visionOFFSIDES
66Accidental drug intake by childOFFSIDES
67Acute Coronary SyndromeSIDER
68Acute otitis mediaOFFSIDES
69AlopeciaOFFSIDES
SIDER
70AngioedemaSIDER
71Angle Closure GlaucomaSIDER
72AnhidrosisOFFSIDES
73AnorexiaOFFSIDES
74AnorgasmiaOFFSIDES
SIDER
75Anticholinergic SyndromeOFFSIDES
76Apparent deathOFFSIDES
77Autologous bone marrow transplantation therapyOFFSIDES
78Bacteria stool identifiedOFFSIDES
79Blood 1,25-dihydroxycholecalciferol decreasedOFFSIDES
80Blood cholesterol increasedSIDER
81Blood corticotrophin increasedOFFSIDES
82Blood prolactin increasedSIDER
83Blood triglycerides increasedSIDER
84Blurred visionOFFSIDES
85Breast cancer stage IIOFFSIDES
86BruxismSIDER
87Cardiac ablationOFFSIDES
88Cerebral ArteriosclerosisOFFSIDES
89ChillsSIDER
90ClumsinessOFFSIDES
91Coagulation test abnormalOFFSIDES
92CryingCanada Vigilance: 1Canada Vigilance
OFFSIDES
93Deafness NeurosensoryOFFSIDES
94Decreased LibidoOFFSIDES
95DermatitisSIDER
96Device occlusionOFFSIDES
97DiarrheaOFFSIDES
98Disturbance in sexual arousalSIDER
99DrowsinessOFFSIDES
100Drug screen positiveOFFSIDES
101Drug withdrawal headacheOFFSIDES
102DysgeusiaOFFSIDES
SIDER
103Ear and labyrinth disordersSIDER
104Ear discomfortOFFSIDES
105EcholaliaOFFSIDES
106Eosinophilic PneumoniaSIDER
107EpistaxisSIDER
108Erectile dysfunctionSIDER
109Erythema MultiformeSIDER
110Erythema NodosumOFFSIDES
111Essential TremorOFFSIDES
112Excessive sexual fantasiesOFFSIDES
113Expired drug administeredOFFSIDES
114FastingSIDER
115Feeling of body temperature changeOFFSIDES
116FlatulenceOFFSIDES
117Foaming at mouthOFFSIDES
118FolliculitisOFFSIDES
119FormicationOFFSIDES
120FrustrationOFFSIDES
121Gastrointestinal sounds abnormalOFFSIDES
122GlaucomaOFFSIDES
123Hearing aid userOFFSIDES
124HostilityOFFSIDES
125HypersensitivitySIDER
126Hypoaesthesia facialOFFSIDES
127HypomaniaSIDER
128Impaired driving abilityOFFSIDES
129Inhalation TherapyOFFSIDES
130Injection site warmthOFFSIDES
131Intentional drug misuseOFFSIDES
132LazinessOFFSIDES
133Limb discomfortOFFSIDES
134LipohypertrophyOFFSIDES
135Male sexual dysfunctionOFFSIDES
136MalnutritionSIDER
137Mechanical urticariaOFFSIDES
138Medication residueOFFSIDES
139Micturition frequency decreasedOFFSIDES
140Middle insomniaOFFSIDES
141Motion SicknessOFFSIDES
142Myocardial InfarctionSIDER
143Negative thoughtsOFFSIDES
144Nervous tensionOFFSIDES
145NervousnessSIDER
146Nipple painOFFSIDES
147Nonspecific reactionOFFSIDES
148OnychoclasisOFFSIDES
149Oropharyngeal painOFFSIDES
150Orthostatic hypertensionOFFSIDES
151Pain of skinOFFSIDES
152ParaparesisOFFSIDES
153ParaplegiaOFFSIDES
154ParasystoleOFFSIDES
155Poor quality sleepCanada Vigilance: 1Canada Vigilance
OFFSIDES
156Protein urine presentSIDER
157ProteinuriaSIDER
158Red blood cell burr cells presentOFFSIDES
159RhonchiOFFSIDES
160Schizoid Personality DisorderOFFSIDES
161Serotonin SyndromeSIDER
162ShockSIDER
163Sleep TalkingOFFSIDES
164Stevens-Johnson SyndromeSIDER
165Suppressed lactationOFFSIDES
166SyncopeSIDER
167TachyphreniaOFFSIDES
168TachyphylaxisOFFSIDES
169TensionSIDER
170Testicular massOFFSIDES
171Therapeutic response unexpectedOFFSIDES
172TinnitusOFFSIDES
SIDER
173Toxic Epidermal NecrolysisSIDER
174Unevaluable eventOFFSIDES
175Urinary RetentionSIDER
176Urinary hesitationSIDER
177VertigoSIDER
178Violence-related symptomOFFSIDES
179Vitamin A DeficiencyOFFSIDES
180Weight decreasedSIDER
181White blood cell agglutination presentOFFSIDES
182Wrong technique in drug usage processOFFSIDES
183nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.